Shufro Rose & CO LLC Akebia Therapeutics, Inc. Transaction History

Shufro Rose & CO LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 28, 2020	SELL	$3.16 - $6.73 $88,382 - $188,231	-27,969 Closed	0 $0
Q3 2019 Oct 30, 2019	SELL	$3.55 - $5.4 $3,983 - $6,058	-1,122 Reduced 3.86%	27,969 $110,000
Q2 2019 Jul 24, 2019	BUY	$4.1 - $8.05 $2,722 - $5,345	664 Added 2.34%	29,091 $141,000
Q1 2019 May 03, 2019	SELL	$5.41 - $8.73 $3,035 - $4,897	-561 Reduced 1.94%	28,427 $233,000
Q4 2018 Feb 01, 2019	BUY	$5.39 - $9.15 $156,245 - $265,240	28,988 New	28,988 $160,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Shufro Rose & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Shufro Rose & CO LLC with notifications on news.